U.S. Stem Cell, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 0.082049 million compared to USD 0.200749 million a year ago. Net loss was USD 2.86 million compared to USD 3.29 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | 0.00% |
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 66.15K | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- USRM Stock
- News U.S. Stem Cell, Inc.
- U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022